Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 3Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Multiple Myeloma 2Leukemia 2Thrombocytopenia 1Testicular Germ Cell Tumor 1Prostatic Neoplasms 1Precancerous Conditions 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Graft vs Host Disease 1Gestational Trophoblastic Disease 1Fanconi Anemia 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1Anemia 1

Interventions

Cyclophosphamide 27Cyclosporine 22fludarabine phosphate 21Busulfan 19Peripheral Blood Stem Cell Transplantation 16Antilymphocyte Serum 16Radiotherapy 15Mycophenolic Acid 15Cord Blood Stem Cell Transplantation 15Whole-Body Irradiation 13Methotrexate 11Methylprednisolone 10Filgrastim 9Cytarabine 7Tacrolimus 6Melphalan 6Etoposide 6sargramostim 4fludarabine 4Thiotepa 4Decitabine 4Azacitidine 4Granulocyte Colony-Stimulating Factor 3Cyclosporins 3Arsenic Trioxide 3merphos 2Vorinostat 2Topotecan 24-phenylbutyric acid 2vatalanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory × Microarray Analysis × Myeloid × Clear all
NCT01165996 2019-03-04

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Case Comprehensive Cancer Center

Phase 1/2 Completed
25 enrolled 13 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡